DE20119321U1 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation

Info

Publication number
DE20119321U1
DE20119321U1 DE20119321U DE20119321U DE20119321U1 DE 20119321 U1 DE20119321 U1 DE 20119321U1 DE 20119321 U DE20119321 U DE 20119321U DE 20119321 U DE20119321 U DE 20119321U DE 20119321 U1 DE20119321 U1 DE 20119321U1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparation
ginsenosides
preparation according
microapplication
ginsenoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE20119321U
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDIWIRK GmbH
Original Assignee
MEDIWIRK GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDIWIRK GmbH filed Critical MEDIWIRK GmbH
Priority to DE20119321U priority Critical patent/DE20119321U1/en
Publication of DE20119321U1 publication Critical patent/DE20119321U1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)

Description

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßtThe description text was not recorded electronically

Claims (6)

1. Pharmazeutisches Präparat, gekennzeichnet durch eine Gehalt an mindestens 1 Ginsenosid in einer Mikroapplikationshülle.1. Pharmaceutical preparation, characterized by a content of at least 1 ginsenoside in a microapplication sleeve. 2. Pharmazeutisches Präparat nach Anspruch 1, dadurch gekennzeichnet, dass die Mikroapplikationshülle ein Liposom, oder ein Nanopartikel ist oder die Mikroapplikationshülle eine mehrschichtige Membran aufweist.2. Pharmaceutical preparation according to claim 1, characterized characterized in that the microapplication envelope is a liposome, or a The nanoparticle or the microapplication shell is a multilayer Has membrane. 3. Pharmazeutisches Präparat nach Anspruch 1, dadurch gekennzeichnet, dass das Liposom vorzugsweise aus einer Lipidkomposition an sich bekannter Art, besonders bevorzugt aus einer Lipidkomposition mit bekanntem Targeting gebildet ist.3. Pharmaceutical preparation according to claim 1, characterized characterized in that the liposome preferably from a Lipid composition known per se, particularly preferably from one Lipid composition with known targeting is formed. 4. Pharmazeutisches Präparat nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass das Präparat mindestens 1 Ginsenosid aus der Gruppe der Aglykon (20S)-Protopanaxadiole und/oder der Gruppe der Aglykon (20S)-Protopanaxtriole und/oder der Gruppe Aglykon Oleanolsäure enthält.4. Pharmaceutical preparation according to one of claims 1 to 3, characterized characterized in that the preparation at least 1 ginsenoside from the Group of aglycon (20S) protopanaxadiols and / or the group of Aglycone (20S) protopanaxtriols and / or the aglycone group Contains oleanolic acid. 5. Pharmazeutisches Präparat nach Anspruch 4, dadurch gekennzeichnet, dass Aglykon (20S)-Protopanaxadiol die Ginsenoside Ra, Ra2, Ra3, Rb1, Rb2, Rb3, Notoginsenosid R4, Rs1, Rs2 und die Malonylginsenoside Rb1, Rc und Rd, Aglykon (20S)-Protopanaxtriol die Ginsenoside Re, Rf, Rg1 und das Notogrinsenosid R1 und Aglykon Oleanolsäure die Ginsenoside Ro und Chikusetsusasaponin-V enthält.5. Pharmaceutical preparation according to claim 4, characterized characterized that aglycone (20S) -protopanaxadiol the ginsenosides Ra, Ra2, Ra3, Rb1, Rb2, Rb3, Notoginsenosid R4, Rs1, Rs2 and the  Malonylginsenoside Rb1, Rc and Rd, Aglykon (20S) -Protopanaxtriol die Ginsenoside Re, Rf, Rg1 and the Notogrinsenosid R1 and Aglykon Oleanolic acid containing ginsenosides Ro and Chikusetsusasaponin-V. 6. Pharmazeutisches Präparat nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass das Präparat die Ginsenoside R1, R4, Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rs1, Rs21, Ro oder Chikusetsusasaponin-V einzeln oder mehrere der genannten Ginsenoside im Gemisch oder Metaboliten der genannten Ginsenoside oder die genannten Ginsenoside in Kombination mit anderen über an die Mikroapplikationshülle gekoppelte Liganden verbundenen Wirkstoffen enthält.6. Pharmaceutical preparation according to one of claims 1 to 3, characterized characterized in that the preparation contains the ginsenosides R1, R4, Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rs1, Rs21, Ro oder Chikusetsusasaponin-V individually or several of the named Ginsenosides in a mixture or metabolites of the ginsenosides mentioned or the ginsenosides mentioned in combination with others via the Microapplication-coupled ligand-linked drugs contains.
DE20119321U 2001-11-19 2001-11-19 Pharmaceutical preparation Expired - Lifetime DE20119321U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE20119321U DE20119321U1 (en) 2001-11-19 2001-11-19 Pharmaceutical preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE20119321U DE20119321U1 (en) 2001-11-19 2001-11-19 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
DE20119321U1 true DE20119321U1 (en) 2002-05-29

Family

ID=7964528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE20119321U Expired - Lifetime DE20119321U1 (en) 2001-11-19 2001-11-19 Pharmaceutical preparation

Country Status (1)

Country Link
DE (1) DE20119321U1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026924A1 (en) * 2004-09-08 2006-03-16 Zelin Li The use of ginsenoside in the treatment of aids
EP2036566A1 (en) * 2006-06-09 2009-03-18 Shanghai Innovative Research Center Of Traditional Chinese Medicine Use of 20(s)-protopanoxadiol in manufacture of antidepressants
US20130040903A1 (en) * 2007-11-30 2013-02-14 Zuoguang Zhang Pharmaceutical compositions for treating depression and anxiety
WO2014178803A1 (en) * 2013-04-29 2014-11-06 Alkoçlar Erdal Can A composition for use in the treatment of alcohol addiction
CN105998115A (en) * 2016-05-16 2016-10-12 江西中医药大学 Breviscapine-panax notoginseng saponins double-pharmaceutical nano-composite particle and preparation method and application thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026924A1 (en) * 2004-09-08 2006-03-16 Zelin Li The use of ginsenoside in the treatment of aids
EP2036566A1 (en) * 2006-06-09 2009-03-18 Shanghai Innovative Research Center Of Traditional Chinese Medicine Use of 20(s)-protopanoxadiol in manufacture of antidepressants
EP2036566A4 (en) * 2006-06-09 2011-06-15 Shanghai Innovative Res Ct Of Traditional Chinese Medicine Use of 20(s)-protopanoxadiol in manufacture of antidepressants
US20130040903A1 (en) * 2007-11-30 2013-02-14 Zuoguang Zhang Pharmaceutical compositions for treating depression and anxiety
WO2014178803A1 (en) * 2013-04-29 2014-11-06 Alkoçlar Erdal Can A composition for use in the treatment of alcohol addiction
CN105998115A (en) * 2016-05-16 2016-10-12 江西中医药大学 Breviscapine-panax notoginseng saponins double-pharmaceutical nano-composite particle and preparation method and application thereof

Similar Documents

Publication Publication Date Title
Shin et al. Chemical diversity of ginseng saponins from Panax ginseng
Felipe et al. Phytochemical analysis of Pfaffia glomerata inflorescences by LC-ESI-MS/MS
KASAI et al. Saponins of red ginseng
Ragasa et al. Triterpenes from Euphorbia hirta and their cytotoxicity
Tian et al. Saponins: the potential chemotherapeutic agents in pursuing new anti-glioblastoma drugs
EP2643534B2 (en) Building envelope element comprising a thermal insulating element
DE20119321U1 (en) Pharmaceutical preparation
Zu et al. Recent development in the synthesis of natural saponins and their derivatives
Gaidi et al. Saponins-mediated potentiation of cisplatin accumulation and cytotoxicity in human colon cancer cells
Klenk et al. Über die Gehirnganglioside
DE2458650B2 (en) Low energy foods
Pelzer et al. Steroidkonjugate I. Hochspannungs-papierelektrophorese von 17-ketosteroidkonjugaten
Xue-Ni et al. Research progress on naturally-occurring and semi-synthetic ocotillol-type ginsenosides in the genus Panax L.(Araliaceae)
WO2003045410A1 (en) Pharmaceutical preparation containing micro-encapsulated or nano-encapsulated ginsenosides
EP3242981B1 (en) Quick construction wall
Engler „Allerdings ist die Lektüre äusserst schwierig.“ Zum Verhältnis von Moritz Schlick und Ludwig Wittgenstein
JPH08119866A (en) Antitumor agent
Yang et al. Bioactive triterpenoid and steroid saponins from medicinal plants in southwest China
Mohammed Constituents of Colubrina elliptica Cecropia peltata and Entada polystachya
Ayoola et al. Justifying the antidiabetic ethnomedicinal claim of Massularia acuminata through its antihyperglycaemic activity
DE1515832A1 (en) Coaxial radio frequency cable
Kakhro Die Schweizer Wenkersätze
Dagang et al. Oligo‐and macrocyclic diterpenes in thymelaeaceae and euphorbiaceae occurring and utilized in yunnan (Southwest China) 3. Two new daphnane type 9, 13, 14‐orthoesters from Wikstroemia mekongenia
Vatter et al. Swiss Federalism from a Comparative Perspective–Dealing with Reform Obstacles
Khachatryan et al. The Evolution of foreign policy of the Federal Republic of Germany (1966-1974)(in German)

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20020704

R156 Lapse of ip right after 3 years

Effective date: 20050601